Korro Bio, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.2% | -26.3% | -0.7% | +20.0% | +44.9% | -2.2% | -2.0% | +0.0% | -19.4% | -60.5% | -5.0% | – | |
| – | +203.7% | -29.5% | +11.8% | +31.6% | +6.6% | +29.8% | +13.5% | -8.7% | +13.5% | +31.9% | -1.0% | – | |
| – | -42.2% | -304.5% | – | -36.3% | +280.7% | -134.6% | – | -171.6% | – | – | -808.2% | – | |
| – | +3,044.7% | -27.5% | +6.2% | -18.2% | -70.2% | -91.8% | +17.6% | +25.0% | -52.0% | -75.0% | +76.2% | – | |
| – | -2,800.8% | -72.4% | +1,724.9% | -87.7% | -78.0% | – | -134.5% | – | +96.4% | -316.1% | -44.5% | – | |
| – | – | -99.9% | +48,501.4% | -98.9% | +28.0% | -81.5% | -97.1% | +2,460.0% | +196.9% | +23,113.7% | -103.3% | – | |
| – | +6,264.5% | -121.4% | – | – | – | – | -447.4% | – | – | – | -194.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.